Nanobiotix Shares Dip 4.14% at Close Despite Secured Funding
On Monday, November 24, 2025, Nanobiotix announced the completion of its non-dilutive financing agreement with Healthcare Royalty for up to $71 million, with an initial payment of $50 million and an additional $21 million expected in a year under certain conditions. This financing extends the biotech's cash visibility until early 2028. Healthcare Royalty will be compensated and repaid through a capped portion of the royalties on sales of JNJ-1900 (NBTXR3) due to Nanobiotix under the licensing agreement with Janssen. Despite this strategic operation praised by management, the biotechnology company's stock closed lower this Tuesday.
Stock Performance and Market Reaction
Nanobiotix's stock ended the session on Tuesday, November 25, at 18.04 euros, down 4.14% from the previous day's close of 18.82 euros, in a context where the CAC 40 was up by 0.83% at 8,025.8 points. Trading remained moderate with 0.47% of the capital traded during the day. This decline comes the day after the announcement of the completion of the strategic financing with Healthcare Royalty, suggesting profit-taking following the recent sharp rise in the stock. From a broader perspective, the stock has shown remarkable performance with a 415.4% increase over the year, significantly outperforming the CAC 40, which gained 10.62% over the same period. Over three months, the stock has seen a spectacular jump of 114.3%, particularly driven by the advancements of the JNJ-1900 (NBTXR3) program with the first data from a Phase 1 study in esophageal cancer. However, the weekly dynamic remains negative with a decline of 7.77% over the last seven days, reflecting a consolidation phase after recent surges. The monthly volatility of the stock stands at 30.68, confirming the typical speculative profile of a biotech in advanced clinical phase. The beta of 0.44 indicates a relative decorrelation with general market movements, with the stock evolving more independently than the reference index.
Technical Analysis and Stock Positioning
Technical analysis reveals a contrasted positioning for Nanobiotix. The stock is currently fluctuating between a support identified at 13.36 euros and a resistance at 24.00 euros, leaving potential room for progression before testing this technical ceiling. The RSI (Relative Strength Index) stands at 57, placing the stock in a neutral zone without overbought or oversold signals, allowing for movement in either direction. The moving averages convey a constructive message: the current price of 18.04 euros is positioned above the 50-day moving average (MM50) at 17.32 euros, confirming a short-term bullish trend. The gap with the 200-day moving average (MM200) at 7.67 euros remains particularly significant, demonstrating the magnitude of the technical rebound engaged over several months. The Bollinger Bands, framing the course between 15.41 euros (lower bound) and 19.98 euros (upper bound), suggest that the stock is approaching the upper limit of its current volatility channel. The Scholes signal indicates a buy position, while the MACD histogram displays a positive value at 0.16, confirming a bullish momentum even if it remains moderate. The Chaikin Money Flow (CMF) slightly negative at -0.05 however reflects some investor caution, potentially reflecting the ongoing consolidation phase after substantial gains recorded in recent months.
Beyond Financing: Clinical Updates and Investor Movements
Beyond the financing, Nanobiotix has confirmed the completion of the sponsorship transfer of the Phase 3 NANORAY-312 study in head and neck cancer to Johnson & Johnson in most regions, and announced promising first data in esophageal cancer. The company is expecting clinical updates in 2026 from Phase 1 studies in melanoma, lung cancer amenable to re-irradiation, pancreatic cancer, and esophageal cancer. On the shareholder front, Goldman Sachs Group reported to the AMF that it had crossed below the 5% voting rights threshold of Nanobiotix as a result of an off-market share sale on October 29. This movement reflects a repositioning of institutional investors after the strong appreciation of the stock. The company had 20.4 million euros in cash as of September 30, 2025, a position strengthened by the new financing which now secures the financial trajectory until 2028. Tuesday's session illustrates the characteristic oscillations of biotechnological values, where profit-taking can quickly follow positive announcements, even when these structurally strengthen the company's position. Investors will now monitor the evolution of clinical programs in 2026, crucial for medium-term valuation.
